Plus new data that suggests that payers think Part D plans will get more expensive and less generous under the IRA
And PhRMA's research chiefs have some advice for Biden about moonshots
And more data that suggests that hospitals are not spending their 340B windfalls on charity care
And a gentle warning that arguing against cost-effectiveness of obesity meds will not age well
And another company says that the IRA is influencing drug-development decisions
And Happy Friday the 13th 👻👻👻
Plus a link to a good piece on prescription drug affordability boards
And a PBM-sponsored survey shows that employers love PBMs
And 'tis the season to think deeply about health insurance
And the Economist has the headline of the week
And Cencora pushes a takedown of ICER's approach to gene therapy
And a useful link on the most important part of the IRA that no one (but you all) has heard of